GGrantIndex
Sort

261,768 grants matching gene therapy

Primary Immune Deficiency Treatment Consortium

$1,249,464
Morton Cowan · University Of California, San Francisco · U54 · FY2014 · AI

Autoimmune Drivers and Protectors Team Science (ADAPTS)

$1,249,430
Judith A James · Oklahoma Medical Research Foundation · U01 · FY2025 · AI

Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage

$1,249,427
Harold A Chapman · University Of California, San Francisco · U01 · FY2018 · HL

Comparative Analysis of Cancer-Associated Genes and Development of a Gene Delive

$1,249,380
Vladimir Larionov · Basic Sciences · Z01 · FY2007 · CA

Pathogenesis of Rett Syndrome

$1,249,276
Hugo W. Moser Res Inst Kennedy Krieger · P01 · FY2003 · HD

Rare disease CRC for new therapies and new diagnostics

$1,249,253
Baylor College Of Medicine · U54 · FY2005 · RR

Inherited Ocular Diseases

$1,249,198
James F. Hejtmancik · National Eye Institute · ZIA · FY2012 · EY

Transcription and Therapy for HD: from Molecules to Man

$1,249,142
Massachusetts General Hospital · P01 · FY2005 · NS

TAMAXIFEN PHARMACOGENETICS

$1,249,122
Georgetown University · U01 · FY2000 · GM

Cannabinoid CB1 and CB2 receptors and drug abuse

$1,248,919
Zheng-Xiong Xi · National Institute On Drug Abuse · ZIG · FY2021 · DA

P1 - Molecular Mechanisms of KIT Signaling and Imatinib Resistance in GIST

$1,248,914
Cristina R Antonescu · Sloan-Kettering Inst Can Research · P50 · FY2010 · CA

Personalized Cystic Fibrosis Therapy and Research Center

$1,248,906
Anjaparavanda P Naren · Cincinnati Childrens Hosp Med Ctr · P30 · FY2025 · DK

Defining and Manipulating Epigenomic Regulators in Endogenous Systems

$1,248,825
Jordan Leslie Meier · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

RARE DISEASE CRC FOR NEW THERAPIES AND NEW DIAGNOSTICS

$1,248,799
Baylor College Of Medicine · U54 · FY2004 · RR

Rare disease CRC for new therapies and new diagnostics

$1,248,799
Baylor College Of Medicine · U54 · FY2004 · RR

Porphyria Rare Disease Clinical Research Consortium (RDCRC)

$1,248,797
Robert J Desnick · Icahn School Of Medicine At Mount Sinai · U54 · FY2015 · DK

Restoration of free radical homeostasis: novel therapy of septic shock

$1,248,631
Andrew L Salzman · Radikal Therapeutics, Inc. · R44 · FY2016 · GM

GENETIC APPROACHES FOR CANCER IMMUNOTHERAPY

$1,248,539
University Of Michigan At Ann Arbor · P01 · FY2000 · CA

Rare disease CRC for new therapies and new diagnostics

$1,248,331
Baylor College Of Medicine · U54 · FY2003 · RR

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML

$1,248,330
Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2019 · CA

From therapeutic mechanisms to unraveling the pathophysiology of MS

$1,248,280
Bibiana Bielekova · National Institute Of Neurological Disorders And Stroke · ZIA · FY2015 · NS

Transcription and Therapy for HD: from Molecules to Man

$1,248,267
Massachusetts General Hospital · P01 · FY2004 · NS

Molecular and Cellular Therapies for Muscular Dystrophy

$1,248,156
Stanley C Froehner · University Of Washington · P01 · FY2008 · NS

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin

$1,248,082
John E Harris · Univ Of Massachusetts Med Sch Worcester · U01 · FY2024 · AI

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin

$1,248,082
John E Harris · Univ Of Massachusetts Med Sch Worcester · U01 · FY2025 · AI